Carisma Therapeutics (CARM) Projected to Post Quarterly Earnings on Monday

Posted by Defense World Staff on Mar 28th, 2026

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) is expected to release its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect the company to announce earnings of ($0.1474) per share and revenue of $4.2290 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Carisma Therapeutics Stock Down 0.3%

NASDAQ:CARM opened at $0.03 on Friday. The stock has a fifty day simple moving average of $0.04 and a 200 day simple moving average of $0.09. The firm has a market capitalization of $1.38 million, a price-to-earnings ratio of 0.05 and a beta of 1.86. Carisma Therapeutics has a 1-year low of $0.03 and a 1-year high of $1.27.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Carisma Therapeutics stock. Jane Street Group LLC acquired a new stake in Carisma Therapeutics Inc. (NASDAQ:CARM – Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 0.36% of Carisma Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

(Get Free Report)

Carisma Therapeutics, Inc is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors.